Pacira BioSciences Inc (PCRX) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Hi, good morning. Welcome to the Jefferies Healthcare Conference in New York, day one. My name is Dennis Singh, biotech analyst here at Jefferies. I have the pleasure of having Paseer Biosciences CEO, Frank Lee, here with us. Welcome. Frank, maybe to kind of kick things off, just give a brief overview of the company for those who aren't familiar. Just talk about the business and, you know, how things have evolved over the last ...

Core Insights - PharmaCorp Rx Inc. reported a net income of $254,000 for Q1 2025, marking its first quarter of positive net income [2][3] - The company has entered into non-binding letters of intent to acquire four community pharmacies for approximately $12.5 million, aligning with its acquisition-driven growth strategy [5][6] Financial Performance - Same-store sales increased by 4.0% year-over-year compared to Q1 2024, indicating organic growth across the pharmacy network [3] - Total prescription volumes rose by 3.2% year-over-year, reflecting sustained patient engagement [4] Acquisition Strategy - The proposed acquisitions are expected to be accretive to earnings and will be funded through a combination of cash and common shares [5][6] - The completion of these acquisitions is subject to the execution of definitive agreements and customary conditions, with anticipated closings between June 30 and August 31, 2025 [7] Operational Outlook - The company remains committed to expanding its national footprint through strategic acquisitions and operational excellence [9] - Management expresses confidence that the momentum from Q1 results will continue to build in future quarters [3][9]

Pacira BioSciences Inc (PCRX) 2025 Conference May 21, 2025 08:30 AM ET Speaker0 Welcome back everyone to the twenty twenty five RBC Global Healthcare Conference. My name is Greg Renza, one of the biotech analysts, and we're pleased to be joined now by Pacira Biosciences. Joining us from the company is the Chief Executive Officer, Frank Lee. Frank, great to see you. Thanks for being here. Speaker1 Good to see you, Greg. Yeah. Happy to be here. Speaker0 Great. Great. Well, always a lot going on in the externa ...

No serious treatment-emergent AEs related to the treatment or procedure were reported regardless of steroid pretreatment or dose level administered. Treatment-related joint effusions (swelling) were the most common AE, occurring in 36% of patients who received steroid pretreatment vs 61% of patients who were not pretreated. The majority of effusions were mild to moderate in severity and resolved in a median of 33 days among patients in the pretreated group. -- Early clinical data indicates that Pre-existing ...

Core Viewpoint - A lawsuit is pending against Pacira BioSciences, Inc. for alleged violations of securities laws related to misleading statements about patent protections for Exparel, which is critical for the company's revenue growth [2]. Group 1: Lawsuit Details - An investor filed a lawsuit on January 13, 2025, claiming that Pacira made false statements regarding the patent protections for Exparel, which accounts for approximately 80% of the company's revenue [2]. - The lawsuit alleges that Pacira misrepresented the strength of the '495 patent, which was invalidated in a separate case, leading to concerns that generic competition could arise during the patent's life [2]. Group 2: Investor Information - Shareholders who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold them are encouraged to contact the Shareholders Foundation for options regarding the lawsuit [1][3].

1Q25 Earnings PCRX | May 2025 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as ...

Core Viewpoint - Pacira BioSciences reported first-quarter 2025 adjusted earnings of 62 cents per share, exceeding the Zacks Consensus Estimate of 57 cents, while total revenues of $168.9 million fell short of the expected $175 million [1][2] Financial Performance - Adjusted earnings for Q1 2025 were 62 cents per share, consistent with the same quarter last year [1] - Total revenues reached $168.9 million, a 1% increase year over year, but missed the Zacks Consensus Estimate [1] - Exparel's net product sales were $136.5 million, up 3% from the previous year, but below the consensus estimate of $140.2 million [2][4] - Zilretta's net product sales were $23.3 million, down 10% year over year, missing both the consensus and model estimates [4] - Iovera's net product sales were $5.1 million, a 2% increase year over year, but below the consensus estimate of $5.5 million [5] Expenses - Research and development (R&D) expenses (excluding stock-based compensation) increased by 41% to $23.1 million due to higher product development and clinical study costs [6] - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) rose 19% to $76.2 million, driven by increased investments in commercial and marketing activities [7] Guidance and Projections - For 2025, Pacira BioSciences expects total revenues between $725 million and $765 million, with an adjusted gross margin projected between 76% and 78% [8] - Adjusted R&D expenses are anticipated to be between $90 million and $105 million, while adjusted SG&A expenses are expected to range from $290 million to $320 million [10] Recent Developments - The company announced the dosing of the first patient in a mid-stage study for pipeline candidate PCRX-201, aimed at treating osteoarthritis of the knee [11] - A settlement agreement with Fresenius and others regarding Exparel patents protects sales from generic competition until at least 2030 [12] - A U.S. District Court ruling eliminated the obligation to pay a low single-digit royalty on Exparel sales, expected to enhance profitability and revenue growth [13]

Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of 5.81%.Over the last four quarters, the company ...

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Susan Mesco - Vice President Investor RelationsFrank Lee - CEO & DirectorJonathan Slonin - Chief Medical OfficerShawn Cross - Chief Financial OfficerAnish Nikhanj - Senior Associate - Biotechnology Equity ResearchBrendan Teehan - Chief Commercial OfficerGary Nachman - Managing Director - Equity ResearchJeevan Larson - Equity Research Associate Conference Call Participants Hardik Parikh - Equity Research Analyst ...

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Pacira Biosciences Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be the question and answer session. Speakers' there the Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, S ...